Skip to main content

EXOSOMAS COMO BIOMARCADORES DE PROGRESION DE LA ENFERMEDAD HEPATICA TRAS LA CURACION DEL VIRUS DE LA HEPATITIS C

PI18/00210

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of Extracellular Vesicle Isolation Methods for miRNA Sequencing

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Martínez-González, Brenda|||0000-0002-4482-5181
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Núñez-Moreno, Gonzalo|||0000-0001-5982-570X
  • Minguez, Pablo|||0000-0003-4099-9421
  • Burgui, Idoia
  • Ramos-Ruiz, Ricardo|||0000-0002-6331-9786
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Rico, Angie
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Piron, Maria|||0000-0001-6858-9374
  • Corrales Insa, Irene|||0000-0002-0647-0340
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Ramírez Serra, Clara|||0000-0001-8971-1711
  • Camós Anguila, Sílvia|||0000-0002-0478-8494
  • Domingo, Esteban
  • Bes, Marta|||0000-0001-6103-072X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin

  • Somovilla, Pilar
  • García-Crespo, Carlos
  • Martínez-González, Brenda
  • Soria, María Eugenia
  • Ávila, Ana Isabel de
  • Gallego, Isabel
  • Mínguez, Pablo
  • Durán-Pastor, Antoni
  • Ferrer-Orta, Cristina
  • Salar-Vidal, Llanos
  • Esteban-Muñoz, Mario
  • Zúñiga Lucas, Sonia
  • Solá Gurpegui, Isabel
  • Enjuanes Sánchez, Luis
  • Esteban, Jaime
  • Fernández-Roblas, Ricardo
  • Gadea, Ignacio
  • Gómez-Castilla, Jordi
  • Verdaguer, Núria
  • Domingo, Esteban
  • Perales, Celia
We report that ribavirin exerts an inhibitory and mutagenic activity on SARS-CoV-2-infecting Vero cells, with a therapeutic index higher than 10. Deep sequencing analysis of the mutant spectrum of SARS-CoV-2 replicating in the absence or presence of ribavirin indicated an increase in the number of mutations, but not in deletions, and modification of diversity indices, expected from a mutagenic activity. Notably, the major mutation types enhanced by replication in the presence of ribavirin were A→G and U→C transitions, a pattern which is opposite to the dominance of G→A and C→U transitions previously described for most RNA viruses. Implications of the inhibitory activity of ribavirin, and the atypical mutational bias produced on SARS-CoV-2, for the search for synergistic anti-COVID-19 lethal mutagen combinations are discussed., This work was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181) and cofinanced by the European Development Regional Fund, “A way to achieve Europe.” The work was also supported by grants CSIC-COV19-014 from Consejo Superior de Investigaciones Científicas (CSIC), project 525/C/2021 from Fundació La Marató de TV3, PID2020-113888RB-I00 and 202220I116 from Ministerio de Ciencia e Innovación, BFU2017-91384-EXP from Ministerio de Ciencia, Innovación y Universidades (MCIU), PI18/00210 and PI21/00139 from Instituto de Salud Carlos III, and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). This research work was also funded by the European Commission-NextGenerationEU (regulation EU 2020/2024) through the CSIC’s Global Health Platform (PTI Salud Global). C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001), cofinanced by the European Regional Development Fund (ERDF). CIBERehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas) is funded by Instituto de Salud Carlos III. Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN). C.G.-C. is supported by predoctoral contract PRE2018-083422 from MCIU. P.S. is supported by postdoctoral contract Margarita Salas, CA1/RSUE/2021 from MCIU. B.M.-G. is supported by predoctoral contract PFIS FI19/00119 from ISCIII, cofinanced by Fondo Social Europeo (FSE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus

  • Martínez-González, Brenda
  • Gallego, Isabel
  • Gregori, Josep
  • Soria, María Eugenia
  • Somovilla, Pilar
  • Ávila, Ana Isabel de
  • García-Crespo, Carlos
  • Durán-Pastor, Antoni
  • Briones, Carlos
  • Gómez, Jordi
  • Quer, Josep
  • Domingo, Esteban
  • Perales, Celia
The concept of a mild mutagen was coined to describe a minor mutagenic activity exhibited by some nucleoside analogues that potentiated their efficacy as antiretroviral agents. In the present study, we report the mild mutagen activity of sofosbuvir (SOF) for hepatitis C virus (HCV). Serial passages of HCV in human hepatoma cells, in the presence of SOF at a concentration well below its cytotoxic concentration 50 (CC) led to pre-extinction populations whose mutant spectra exhibited a significant increase of C!U transitions, relative to populations passaged in the absence of SOF. This was reflected in an increase in several diversity indices that were used to characterize viral quasispecies. The mild mutagenic activity of SOF was largely absent when it was tested with isogenic HCV populations that displayed high replicative fitness. Thus, SOF can act as a mild mutagen for HCV, depending on HCV fitness. Possible mechanisms by which the SOF mutagenic activity may contribute to its antiviral efficacy are discussed., The work at CBMSO was supported by grants SAF2014-52400-R from Ministerio de Economía y Competitividad (MINECO); SAF2017-87846-R and BFU2017-91384-EXP from Ministerio de Ciencia, Innovación y Universidades (MCIU); project 525/C/2021 from Fundació La Marató de TV3; PID2020-113888RB-I00 and 202220I116 from Ministerio de Ciencia e Innovación (MICINN); PI18/00210, PI19/00301, PI21/00139, and PI22/00258 from Instituto de Salud Carlos III (ISCIII); S2013/ABI-2906 (PLATESA from Comunidad de Madrid/FEDER); and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). This research work was also funded by the European Commission-NextGenerationEU (regulation EU 2020/ 2094) through the CSIC’s Global Health Platform (PTI Salud Global). C.P. is supported by the Miguel Servet program of the ISCIII (CP14/00121 and CPII19/00001), cofinanced by the European Regional Development Fund (ERDF). B.M.-G. is supported by the predoctoral contract PFIS FI19/00119 from ISCIII, cofinanced by Fondo Social Europeo (FSE), “El FSE invierte en tu futuro”. C.G.-C. is supported by the predoctoral contract PRE2018-083422 from MCIU. P.S. is supported by the postdoctoral contract Margarita Salas, CA1/RSUE/ 2021 from MCIU. A.D.-P. is supported by the contract 13-2022-008566 cofinanced by the Comunidad de Madrid, through the Programa Investigo, en el marco del Plan de Recuperación, Transformación y Resiliencia, financed by the European Union-Next Generation EU. CIBERehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas), which is funded by ISCIII. The work at CAB was supported by the MICINN grant no. PID2019-104903RB-I00. Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fluoride anodic films on stainless-steel fomites to reduce transmission infections

  • Conde del Campo, Ana
  • Voces, Daniel
  • Medel-Plaza, Marina
  • Perales, Celia
  • Ávila, Ana Isabel de
  • Aguilera-Correa, John-Jairo
  • Damborenea, Juan de
  • Esteban, Jaime
  • Domingo, E.
  • Arenas, M. A.
The growing concern arising from viruses with pandemic potential and multi-resistant bacteria responsible for hospital-acquired infections and outbreaks of food poisoning has led to an increased awareness of indirect contact transmission. This has resulted in a renewed interest to confer antimicrobial properties to commonly used metallic materials. The present work provides a full characterization of optimized fluoride anodic films grown in stainless steel 304L as well as their antimicrobial properties. Antibacterial tests show that the anodic film, composed mainly of chromium and iron fluorides, reduces the count and the percentage of the area covered by 50% and 87.7% for Pseudomonas aeruginosa and Stenotrophomonas maltophilia, respectively. Virologic tests show that the same treatment reduces the infectivity of the coronavirus HCoV-229E-GFP, in comparison with the non-anodized stainless steel 304L. IMPORTANCE The importance of environmental surfaces as a source of infection is a topic of particular interest today, as many microorganisms can survive on these surfaces and infect humans through direct contact. Modification of these surfaces by anodizing has been shown to be useful for some alloys of medical interest. This work evaluates the effect of anodizing on stainless steel, a metal widely used in a variety of applications. According to the study, the fluoride anodic layers reduce the colonization of the surfaces by both bacteria and viruses, thus reducing the risk of acquiring infections from these sources., This research has been funded by MCINN, PID2020-112878RB-100/AEI/10.13039/501100011033; the European Commission-Next Generation EU (Regulation EU2020/2024) through CSIC's Global Health Platform (PTI Salud Global), and PIE-CSIC 202060E194. This work was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181), and co-financed by European Development Regional Fund "A way to achieve Europe." The work was also supported by grants CSIC-COV19-014 from Consejo Superior de Investigaciones Científicas (CSIC), project 525/C/2021 from Fundació La Marató de TV3, PID2020-113888RB-I00 and 202220I116 from Ministerio de Ciencia e Innovación, PI18/00210 and PI21/00139 from Instituto de Salud Carlos III, and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens Revull, Meritxell
  • Costafreda Salvany, Maria Isabel
  • Rico Blazquez, Angie
  • Guerrero Murillo, Mercedes
  • Soria Benito, Maria Eugenia
  • Piriz Ruzo, Sofia Romina
  • Vargas Accarino, Elena
  • Gabriel Medina, Pablo
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Esteban Mur, Juan Ignacio
Fibrosi hepàtica; Cèl·lules T; Teràpia de citocines, Fibrosis hepática; Células T; Terapia de citocinas, Liver fibrosis; T cells; Cytokine therapy, Background & aims HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. Methods We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. Results We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Conclusions Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA’s therapies., This study was funded by Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF): grant numbers PI16/00337, PI18/00210 and PI19/00301. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001) cofinanced by the European Regional Development Fund (ERDF).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus

  • García-Crespo, Carlos|||0000-0001-6561-5389
  • Gallego, Isabel
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • de Ávila, Ana Isabel
  • Martínez-González, Brenda|||0000-0002-4482-5181
  • Vázquez-Sirvent, Lucía
  • Lobo-Vega, Rebeca|||0000-0002-4882-6763
  • Moreno del Olmo, Elena|||0000-0002-2301-4558
  • Gómez, Jordi
  • Briones Llorente, Carlos|||0000-0003-2213-8353
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Domingo, Esteban
  • Perales Viejo, Celia|||0000-0003-1618-1937
Replication of RNA viruses is characterized by exploration of sequence space which facilitates their adaptation to changing environments. It is generally accepted that such exploration takes place mainly in response to positive selection, and that further diversification is boosted by modifications of virus population size, particularly bottleneck events. Our recent results with hepatitis C virus (HCV) have shown that the expansion in sequence space of a viral clone continues despite prolonged replication in a stable cell culture environment. Diagnosis of the expansion was based on the quantification of diversity indices, the occurrence of intra-population mutational waves (variations in mutant frequencies), and greater individual residue variations in mutant spectra than those anticipated from sequence alignments in data banks. In the present report, we review our previous results, and show additionally that mutational waves in amplicons from the NS5A-NS5B-coding region are equally prominent during HCV passage in the absence or presence of the mutagenic nucleotide analogues favipiravir or ribavirin. In addition, by extending our previous analysis to amplicons of the NS3- and NS5A-coding region, we provide further evidence of the incongruence between amino acid conservation scores in mutant spectra from infected patients and in the Los Alamos National Laboratory HCV data banks. We hypothesize that these observations have as a common origin a permanent state of HCV population disequilibrium even upon extensive viral replication in the absence of external selective constraints or changes in population size. Such a persistent disequilibrium-revealed by the changing composition of the mutant spectrum-may facilitate finding alternative mutational pathways for HCV antiviral resistance. The possible significance of our model for other genetically variable viruses is discussed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
  • Rico, Angie
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Soria, Maria Eugenia
  • Píriz-Ruzo, Sofía
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Gabriel-Medina, Pablo|||0000-0003-3079-6364
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Quer, Josep|||0000-0003-0014-084X
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Bes, Marta|||0000-0001-6103-072X
HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA's therapies.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens Revull, Meritxell
  • Costafreda Salvany, Maria Isabel
  • Rico Blazquez, Angie
  • Guerrero Murillo, Mercedes
  • Soria Benito, Maria Eugenia
  • Piriz Ruzo, Sofia Romina
  • Vargas Accarino, Elena
  • Gabriel Medina, Pablo
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Esteban Mur, Juan Ignacio
Fibrosi hepàtica; Cèl·lules T; Teràpia de citocines, Fibrosis hepática; Células T; Terapia de citocinas, Liver fibrosis; T cells; Cytokine therapy, Background & aims HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. Methods We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. Results We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Conclusions Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA’s therapies., This study was funded by Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF): grant numbers PI16/00337, PI18/00210 and PI19/00301. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001) cofinanced by the European Regional Development Fund (ERDF).